Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

A neurotensin analog blocks cocaine-conditioned place preference and reinstatement.

Boules M, Netz R, Fredrickson PA, Richelson E.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):236-9. doi: 10.1097/FBP.0000000000000227.

PMID:
26901162
2.

Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Boules MM, Fredrickson P, Muehlmann AM, Richelson E.

Behav Sci (Basel). 2014 Jun 13;4(2):125-53. doi: 10.3390/bs4020125. eCollection 2014 Jun. Review.

3.

Neurotensin agonist attenuates nicotine potentiation to cocaine sensitization.

Fredrickson P, Boules M, Stennett B, Richelson E.

Behav Sci (Basel). 2014 Jan 22;4(1):42-52. doi: 10.3390/bs4010042. eCollection 2014 Mar.

4.

Mechanism of mesenchymal stem cell-induced neuron recovery and anti-inflammation.

Huang P, Gebhart N, Richelson E, Brott TG, Meschia JF, Zubair AC.

Cytotherapy. 2014 Oct;16(10):1336-44. doi: 10.1016/j.jcyt.2014.05.007. Epub 2014 Jun 11.

PMID:
24927715
5.

New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations.

Corena-McLeod M, Walss-Bass C, Oliveros A, Gordillo Villegas A, Ceballos C, Charlesworth CM, Madden B, Linser PJ, Van Ekeris L, Smith K, Richelson E.

PLoS One. 2013 May 14;8(5):e52147. doi: 10.1371/journal.pone.0052147. Print 2013.

6.

In reply.

Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL.

Mayo Clin Proc. 2013 Apr;88(4):420. doi: 10.1016/j.mayocp.2013.01.020. No abstract available.

PMID:
23541018
7.

Diverse roles of neurotensin agonists in the central nervous system.

Boules M, Li Z, Smith K, Fredrickson P, Richelson E.

Front Endocrinol (Lausanne). 2013 Mar 22;4:36. doi: 10.3389/fendo.2013.00036. eCollection 2013.

8.

Multi-modality: a new approach for the treatment of major depressive disorder.

Richelson E.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1433-1442. Epub 2013 Jan 30.

9.

Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications.

Krystal AD, Richelson E, Roth T.

Sleep Med Rev. 2013 Aug;17(4):263-72. doi: 10.1016/j.smrv.2012.08.001. Epub 2013 Jan 26. Review.

PMID:
23357028
10.

Considerations on safety concerns about citalopram prescribing.

Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL.

Mayo Clin Proc. 2012 Nov;87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24. No abstract available.

11.

NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain.

Smith KE, Boules M, Williams K, Richelson E.

Behav Brain Res. 2012 Jun 15;232(1):93-7. doi: 10.1016/j.bbr.2012.03.044. Epub 2012 Apr 5.

PMID:
22504145
12.

Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action.

Zhu HJ, Appel DI, GrĂ¼ndemann D, Richelson E, Markowitz JS.

Pharmacol Res. 2012 Apr;65(4):491-6. doi: 10.1016/j.phrs.2012.01.008. Epub 2012 Feb 8.

PMID:
22342816
13.

The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Smith KE, Boules M, Williams K, Fauq AH, Richelson E.

Behav Brain Res. 2011 Oct 31;224(2):344-9. doi: 10.1016/j.bbr.2011.06.014. Epub 2011 Jun 21.

14.

Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine.

Boules M, Johnston H, Tozy J, Smith K, Li Z, Richelson E.

Behav Pharmacol. 2011 Sep;22(5-6):573-81. doi: 10.1097/FBP.0b013e3283474a3a.

PMID:
21691202
15.

Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L.

Oliveros A, Heckman MG, Del Pilar Corena-McLeod M, Williams K, Boules M, Richelson E.

J Exp Biol. 2010 Dec 15;213(Pt 24):4232-9. doi: 10.1242/jeb.046318.

16.

A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats.

Boules M, Oliveros A, Liang Y, Williams K, Shaw A, Robinson J, Fredrickson P, Richelson E.

Neuropeptides. 2011 Feb;45(1):9-16. doi: 10.1016/j.npep.2010.09.003. Epub 2010 Nov 2.

PMID:
21047685
17.

Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Lee MR, Hinton DJ, Unal SS, Richelson E, Choi DS.

Alcohol Clin Exp Res. 2011 Jan;35(1):99-107. doi: 10.1111/j.1530-0277.2010.01326.x. Epub 2010 Oct 6.

18.

NT69L blocks ethanol-induced increase of dopamine and glutamate levels in striatum of mouse.

Li Z, Boules M, Richelson E.

Neurosci Lett. 2011 Jan 10;487(3):322-4. doi: 10.1016/j.neulet.2010.10.048. Epub 2010 Oct 23.

PMID:
20974215
19.

New antipsychotic drugs: how do their receptor-binding profiles compare?

Richelson E.

J Clin Psychiatry. 2010 Sep;71(9):1243-4. doi: 10.4088/JCP.10ac06470yel. Review. No abstract available.

PMID:
20923625
20.

Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Li Z, Boules M, Williams K, Gordillo A, Li S, Richelson E.

Neurobiol Dis. 2010 Nov;40(2):467-77. doi: 10.1016/j.nbd.2010.07.011. Epub 2010 Jul 24.

Supplemental Content

Loading ...
Support Center